@stockrock, I’d now put the odds of a near term partnership at...

@stockrock, I’d now put the odds of a near term partnership at <10%. It just seems as if none of the potential partners was interested in taking a 20% stake in OPT for a tiny little $75 MN.

I scratch my head what we are missing here on the whole story of OPT-302 and the wAMD space? Kodiak P3 dataany day making the race with much fewer intervals? Lucentis Port Delivery and Vabysmo/faricimab being enough of an innovation/differentiation for Roche’s franchise? Novartis, Regeneron, Bayer – all sleeping and simultaneously missing the opportunity?

@primaus72, 70-80c you say? Wow, that’s low… But you know what, hard to argue against. Given the situation OPT has put itself in by admitting to be in need of $75 MN to get OPT-302 over the line with no instant fix to it.

I mean, even if they’d preferred not to have an industrial partner on board, why not raising the $75 MN via a traditional placement at let’s say a 10% discount to previous market close? 12,5 MN ADRs at $6: The stock would have washed out for one day or two but recovered thereafter as OPT would now be financed till let’s say Q2 2024. That’s been actually my scenario I’d been waiting for all those months…

Now I am left with no clear idea about the whole story any more.

What are the triggersleft?

- Mar/Apr 2022 (eventually):“P3 trials half way enrolled”

- Sep/Oct 2022: “P3 enrollment complete”

- Nov/Dec 2023: “P3 topline results”